Francesco Zaja

Trieste, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 158 publications

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

Journal: The New England journal of medicine
Published: July 01, 2026

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.

Journal: British journal of haematology
Published: June 10, 2026

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Journal: Hematological oncology
Published: February 14, 2026

Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag.

Outcomes, Treatment Patterns, and Resource Use in European Adults with Immune Thrombocytopenia Treated with Avatrombopag.

Journal: TH open : companion journal to thrombosis and haemostasis
Published: January 05, 2026

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.

Journal: American journal of hematology
Published: December 18, 2025

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Journal: The New England journal of medicine
Published: December 09, 2025

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real-Life Multicenter Experience. Results From the REDOT_MCL Study.

Journal: Hematological oncology
Published: November 17, 2025

Immune Effector Cell-Associated Neurotoxicity Delayed Relapse After Chimeric Antigen Receptor T-Cell Therapy: A Case Report.

Immune Effector Cell-Associated Neurotoxicity Delayed Relapse After Chimeric Antigen Receptor T-Cell Therapy: A Case Report.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: November 17, 2025

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Journal: Annals of hematology
Published: October 13, 2025

Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure.

Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure.

Journal: Journal of hematology & oncology
Published: September 28, 2025

High JAK2V617F allele burden in low-risk PV: an additional recommendation to start "early" cytoreduction? Results from a multicentric study.

High JAK2V617F allele burden in low-risk PV: an additional recommendation to start "early" cytoreduction? Results from a multicentric study.

Journal: Leukemia research
Published: July 24, 2025

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study.

Journal: British journal of haematology
Published: March 31, 2025
Showing 1-12 of 158

Last Updated: 09/26/2026